Factors such as apheresis blood volumes, activity of G-CSF, prior chemotherapy, or pre-apheresis peripheral blood CD34+ cell counts may have contributed to lower apheresis yields observed in the pivotal study in the low-weight NHL patients. This evidence concerns the gene CSF3 and non-Hodgkin lymphoma.